Corvus Pharmaceuticals Inc. ((CRVS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Corvus Pharmaceuticals Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician’s Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.’ The study aims to evaluate the efficacy and safety of soquelitinib compared to standard care in treating specific types of relapsed or refractory T-cell lymphomas, which are challenging to treat and have limited options.
Intervention/Treatment: The study tests soquelitinib, an experimental ITK inhibitor, administered orally at 200 mg twice daily. It is compared against standard care treatments, including belinostat and pralatrexate, which are existing therapies for these lymphomas.
Study Design: This interventional study is randomized and open-label, meaning participants are randomly assigned to treatment groups, and both researchers and participants know which treatment is being administered. It follows a parallel intervention model with the primary purpose of treatment, focusing on comparing the new drug’s effectiveness against standard therapies.
Study Timeline: The study began on August 16, 2024, with the latest update submitted on April 15, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results, which are yet to be submitted.
Market Implications: This study’s progress could significantly impact Corvus Pharmaceuticals’ stock performance, as successful results may enhance investor confidence and market position. The ongoing recruitment phase suggests active interest and potential for future market opportunities, especially in a competitive landscape where effective lymphoma treatments are in demand.
The study is currently recruiting, with further details available on the ClinicalTrials portal.